Zentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. increased its stake in Zentalis Pharmaceuticals by 31.4% to 723,075 shares (about 1.0% ownership, ~$1.09M), and other institutions like AQR and Millennium also materially boosted positions.
• Analysts are mixed with a consensus rating of Hold and an average target of $5.83; Guggenheim raised its target to $10 with a Buy, while several firms maintain Sell or Hold views.
• Insiders have been selling (Vincent Vultaggio sold 29,951 shares; 46,617 shares sold in the last 90 days) as the company recently missed quarterly EPS estimates and continues to report negative earnings.

JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 31.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 723,075 shares of the company's stock after acquiring an additional 172,628 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.00% of Zentalis Pharmaceuticals worth $1,092,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ZNTL. AQR Capital Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 177.6% in the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company's stock valued at $985,000 after acquiring an additional 396,233 shares during the period. Millennium Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock valued at $4,881,000 after acquiring an additional 2,111,951 shares during the period. Qube Research & Technologies Ltd acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $37,000. Sei Investments Co. increased its holdings in shares of Zentalis Pharmaceuticals by 373.1% in the 2nd quarter. Sei Investments Co. now owns 167,100 shares of the company's stock valued at $194,000 after acquiring an additional 131,780 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of Zentalis Pharmaceuticals by 346.3% in the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company's stock valued at $770,000 after acquiring an additional 515,257 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZNTL shares. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. Guggenheim lifted their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research report on Friday. Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Tuesday, March 17th. They issued an "equal weight" rating and a $5.00 price objective on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $5.83.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the sale, the insider directly owned 156,779 shares in the company, valued at approximately $380,972.97. The trade was a 16.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 46,617 shares of company stock worth $113,417. 1.90% of the stock is currently owned by insiders.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $6.61 on Friday. The firm's fifty day moving average price is $2.63 and its 200 day moving average price is $2.06. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.09 and a 1-year high of $6.95. The firm has a market cap of $468.85 million, a price-to-earnings ratio of -3.48 and a beta of 1.65.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.08). As a group, analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.